title: Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
authors.affiliation: Pole des neurosciences CHU Toulouse, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Peaureaux
authors.affiliation: Pole des neurosciences CHU Toulouse, France INSERM UMR 1043 et Université de Toulouse; UPS; France.
authors.forename: Beatrice
authors.initials: B
authors.lastname: Pignolet
authors.affiliation: Pole des neurosciences CHU Toulouse, France.
authors.forename: Damien
authors.initials: D
authors.lastname: Biotti
authors.affiliation: Pole des neurosciences CHU Toulouse, France INSERM UMR 1043 et Université de Toulouse; UPS; France.
authors.forename: Florence
authors.initials: F
authors.lastname: Bucciarelli
authors.affiliation: Pole des neurosciences CHU Toulouse, France.
authors.forename: Jana
authors.initials: J
authors.lastname: Gaina
authors.affiliation: Pole des neurosciences CHU Toulouse, France.
authors.forename: Cristina
authors.initials: C
authors.lastname: Bucur
authors.affiliation: Pole des neurosciences CHU Toulouse, France INSERM UMR 1043 et Université de Toulouse; UPS; France.
authors.forename: Michel
authors.initials: M
authors.lastname: Clanet
authors.affiliation: INSERM UMR 1043 et Université de Toulouse; UPS; France Pole spécialités médicales et pathologies infectieuses, CHU Toulouse, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Martin-Blondel
authors.affiliation: Pole des neurosciences CHU Toulouse, France INSERM UMR 1043 et Université de Toulouse; UPS; France dbrassat@yahoo.fr.
authors.forename: David
authors.initials: D
authors.lastname: Brassat
mesh_terms: D000328:Adult; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007577:JC Virus; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications* / Q000188:drug therapy; D000069442:Natalizumab / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D000068876:Fingolimod Hydrochloride